Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.
Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y, Liu Y, Xiao J, Li Y, Lu L, Ai X, Zhan M, Yuan S, Sun L.
Hou X, et al. Among authors: lu l.
Front Pharmacol. 2018 Feb 8;9:21. doi: 10.3389/fphar.2018.00021. eCollection 2018.
Front Pharmacol. 2018.
PMID: 29472856
Free PMC article.